Extended release amphetamine tablets

A method for improving attention for 13 hours to about 16 hours post-dosing in a patient having attention deficit hyperactivity disorder (ADHD), wherein the method comprises administering a chewable extended release amphetamine tablet to the patient once daily in the morning,

• wherein the chewable extended release amphetamine tablet lacks a pH-dependent coating which provides delayed release to an amphetamine component and, wherein the chewable extended release amphetamine tablet comprises:
• (A) a modified release amphetamine component which comprises at least one modified release, pH-independent, diffusion barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) two or more amphetamines bound to the same cation exchange resin or each bound to a different cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, diffusion barrier coating which provides a modified release to the two or more amphetamines, wherein the two or more amphetamines are at least a d-amphetamine and an l-amphetamine, wherein the d-amphetamine and the l-amphetamine are provided by d-amphetamine and at least one of (d,l)-amphetamine and l-amphetamine,
• wherein the ratio of d-amphetamine to l-amphetamine in (A) is about 3.2 to about 1;
• (B) amphetamine aspartate;
• and
• (C) dextroamphetamine sulfate,
• wherein the patient's attention is improved over untreated ADHD patients as measured in a Permanent Product Measure of Performance (PERMP-T) Total Test.